<DOC>
	<DOC>NCT00873223</DOC>
	<brief_summary>This trial is conducted in the United States. The aim of this clinical trial is to investigate whether chronic liraglutide administration affects the mode of action (pharmacokinetics) of insulin detemir</brief_summary>
	<brief_title>Examination of the Effects of Liraglutide on the Mode of Action of Insulin Detemir</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Diagnosed with type 2 diabetes BMI less than 45.0 kg/m2 Insulin naive Currently treated with Oral AntiDiabetic drugs (OADs) and metformin with a HbA1c between 7.0 and 9.5% or currently treated with metformin only with a HbA1c between 7.0 and 10.0% Any clinically significant disease other than type 2 diabetes Currently using daily insulin Thiazolidinione use or other injectable diabetes medications within the last 3 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>